Pr. Shifrin (Russian winner 2020): Gut microbiota & antibiotics

To celebrate #WorldMicrobiomeDay, the Biocodex Microbiota Institute is handing the floor to national grant winners.

Created 15 June 2022
Updated 13 July 2022
WMD_Foundation KOL Russia 2020

About this article

Created 15 June 2022
Updated 13 July 2022

Pr. Oleg Shifrin

Gastroenterologist of the highest qualification category, Head of the department of chronic diseases of the intestines and pancreas of the University Clinical Hospital No. 2, Doctor of Medical Sciences, professor of the department of propaedeutics of internal diseases, gastroenterology, and hepatology of the First Moscow State Medical University (Sechenov University, Russia).

A member of the group for the development of national clinical guidelinedccc ccs. Fields of interest: diagnostic concept of "pancreatic steatosis" and "steatopancreatitis", clinical relationship between pancreatic steatosis and metabolic syndrome; clinical relationship between the onset of IBD and the further course of the disease to develop personalized patient management scheme; prevalence and clinical features of Helicobacter pylori and clostridial infections in patients with ulcerative colitis.

What has the national grant allowed to discover in your microbiota research area?

The national grant made it possible to study in detail the effect of antibiotic therapy on the qualitative and quantitative changes in the composition of the intestinal microbiota, as well as on the concentration and spectrum of bacterial metabolites - short-chain fatty acids. The effect of antibiotic therapy on selective intestinal permeability was studied for the first time. A relationship has been established between antibiotic therapy and the occurrence of symptoms characteristic of functional diseases of the gastrointestinal tract.

What are the consequences for the patient?

It is expected that the results of the project will make it possible to determine an additional pathogenetic mechanism for the formation of symptoms of functional gastrointestinal diseases and become the basis for developing the optimal way to prevent it

Foundation's winners

Discover other testimonies
BMI 22.20

en_view en_sources

    See also